The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy

Ann Oncol. 2009 Mar;20(3):592-5. doi: 10.1093/annonc/mdn758. Epub 2009 Jan 19.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adenylate Kinase / metabolism*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Cardiomyopathies / prevention & control*
  • Cell Line, Tumor
  • Drug Resistance, Neoplasm*
  • Enzyme Activation
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Metformin / pharmacology
  • Metformin / therapeutic use*
  • Receptor, ErbB-2 / antagonists & inhibitors*

Substances

  • Antineoplastic Agents
  • Hypoglycemic Agents
  • Metformin
  • Receptor, ErbB-2
  • Adenylate Kinase